Global Cancer Diagnostics Market Was Worth US$ 18.41 Billion in 2022, Estimated to Gain CAGR of 12.0% During 2023-2031.

Cancer diagnostics involves identifying and determining the presence, type, and stage of cancer in a patient’s body. It employs various techniques such as imaging, biopsies, and blood tests to detect abnormalities at cellular and molecular levels. Accurate diagnostics are crucial for effective treatment planning and monitoring the progression of the disease.

Consumables are dominating the global cancer diagnostics market within the product category. The consistent demand for reagents, antibodies, and test kits contributes to their dominance. A study published in the journal “Cancer Epidemiology, Biomarkers & Prevention” highlighted the substantial usage of consumables in cancer screening, diagnosis, and monitoring, solidifying their dominant market position.

Global Cancer Diagnostics Market Revenue & Forecast, (US$ Million), 2015 – 2031

COVID-19 Impact Analysis on Global Cancer Diagnostics Market

Before the pandemic, the cancer diagnostics market was on a trajectory of steady growth. Innovations in imaging technologies and molecular diagnostics were enhancing early detection and precision treatments, fostering market expansion. The COVID-19 pandemic brought significant shifts to the cancer diagnostics market. Delayed screenings and disrupted healthcare services impacted diagnosis rates. However, the crisis highlighted the importance of resilient diagnostics. Telemedicine adoption and advancements in at-home testing gained prominence, influencing the market’s direction towards more adaptable and patient-centric solutions.

A key driver in the cancer diagnostics market is the growing emphasis on early detection. The American Cancer Society reported that early diagnosis improves survival rates and treatment outcomes. Innovations like liquid biopsies offer non-invasive methods for detecting cancer-associated biomarkers. A study published in “Cancer Epidemiology, Biomarkers & Prevention” highlighted the potential of such approaches. This driver reflects the industry’s commitment to enhancing patient prognosis by detecting cancers at their nascent stages, guiding timely interventions. The substantial costs associated with advanced cancer diagnostic techniques pose a significant restraint. Expensive instruments, specialized training, and complex procedures contribute to the financial burden. A study in the journal “JAMA Oncology” highlighted the economic challenges patients face due to high diagnostic costs. This restraint can hinder access to cutting-edge diagnostics, impacting timely diagnosis and care.

Breast cancer diagnostics is dominating the global cancer diagnostics market within the application category in 2022. Breast cancer accounts for a significant portion of cancer cases, with a substantial focus on early detection. The American Cancer Society notes that mammography screenings have contributed to reduced mortality rates, underscoring the dominance of breast cancer diagnostics.

North America accounted for ~45.8% of the global cancer diagnostics market in 2022. It boasts advanced healthcare infrastructure and proactive screening programs. According to the American Cancer Society, North America has among the highest cancer screening rates globally, indicating its dominant position in diagnostics.

Competitive Landscape

A few of the players operating in the global cancer diagnostics market are

• Abbott
• BD
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• GE HealthCare
• Hologic, Inc.
• Koninklijke Philips N.V.
• QIAGEN
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.
• Other Industry Participants

Global Cancer Diagnostics Market Report Coverage

Global Cancer Diagnostics Market:

By Product

• Consumables

• • Antibodies
  • Kits & Reagents
  • Probes
  • Other Consumables

• Instruments

• • Pathology-Based Instruments
    • Slide Staining Systems
    • Tissue Processing Systems
    • NGS Instruments
    • Cell Processors
    • PCR Instruments
    • Microarrays
    • Other Pathology-Based Instruments
  • Imaging Instruments
    • CT Systems
    • MRI Systems
    • Ultrasound Systems
    • Mammography Systems
    • Nuclear Imaging Systems
  • Biopsy Instruments

By Application

• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Lung Cancer
• Prostate Cancer
• Skin Cancer
• Blood Cancer
• Kidney Cancer
• Liver Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

By End User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

Report Coverage and Deliverables: 

Table of Contents

.

.

**Exclusive for Multi-User and Enterprise User.

Global Cancer Diagnostics Market Segmentation

By Product